A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase ? Chronic Myelogenous Leukemia (ASC2ESCALATE)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
May 25, 2023
End Date
July 30, 2027
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
May 25, 2023
End Date
July 30, 2027